Daré Bioscience, Inc. (DARE)

Market Cap	28.16M
Revenue (ttm)	2.81M
Net Income (ttm)	-30.16M
Shares Out	100.58M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	554,116
Open	0.287
Previous Close	0.295
Day's Range	0.280 - 0.310
52-Week Range	0.270 - 1.100
Beta	1.21
Analysts	Buy
Price Target	6.00 (+2,042.86%)
Earnings Date	May 9, 2024

About DARE

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product candidates include Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms, as part of menopausal hormone therapy; DARE-VVA1 f...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Ms. Sabrina Martucci Johnson
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: DARE

Financial Performance

In 2023, DARE's revenue was $2.81 million, a decrease of -71.92% compared to the previous year's $10.00 million. Losses were -$30.16 million, -2.54% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is $6.0, which is an increase of 2,042.86% from the latest price.

Price Target

$6.0

(2,042.86% upside)

Analyst Consensus: Buy